Definium Therapeutics, Inc.
NASDAQDefinium Therapeutics enters the back half of August with a curious split: the Street is racing to lift price targets after positive Phase III data, yet the stock has shed 13% over the past month and shorts remain dug in at a meaningful 10.8% of float. The analyst picture is the most active part of the story right now. Targets have been moving sharply upward across the board…
DFTX short interest plummets 26% in one day to 10.8% of float, down from 14.4% on July 23rd, as stock rallies on analyst upgrades.
Definium Therapeutics enters the back half of August with a curious split: the Street is racing to lift price targets after positive Phase III data, yet the stock has shed 13% over the past month and shorts remain dug…
Definium Therapeutics has pulled back 5.4% this week to $44.48, giving back a slice of the 89% one-month gain that followed its June 22 Phase 3 data release — and the question now is whether the defensive posture…
Snapshot as of 23 Sept 2026
Five executives sold shares on the same day. Options traders are buying puts at a 52-week high rate. Short sellers are adding positions into a 30% weekly rally. Definium Therapeutics is flashing a rare convergence of…
Definium Therapeutics enters the last week of June with one of the most dramatic moves in small-cap biotech this month — a 50% weekly gain driven by Phase 3 trial results for DT120, its lead psychiatric drug candidate,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DFTX — free to start on ORTEX.
Sign up for free →Open DFTX on ORTEX